IGMS insider disposals show conversion to cash and contingent rights
Rhea-AI Filing Summary
IGM Biosciences completed a merger in which all outstanding common and non-voting shares were cancelled and converted into cash and contingent value rights. Under the merger agreement, each share of common and non-voting stock was converted into $1.247 in cash plus one contractual contingent value right (CVR) governed by a separate CVR agreement. Reporting person Christina Teng Topsoe reported disposals tied to the transaction: 54,235 shares disposed directly and 10,410,364 shares disposed indirectly (comprised of 10,400,564 and 9,800 shares held through affiliated entities), and 5,044,295 non-voting shares (underlying common shares) were disposed in the derivative table; following the transactions the reported beneficial ownership is zero. The filing states pre-merger shareholdings were held through Topsoe Holding A/S and Pillarcater LLC with related disclosure of shared voting or pecuniary interests.
Positive
- Every share converted into $1.247 cash plus one contractual CVR, providing immediate cash consideration to holders
- Reporting person’s beneficial ownership reduced to zero, indicating completion of the conversion process under the merger
- Form 4 discloses indirect holdings and affiliated entities (Topsoe Holding A/S, Pillarcater LLC), improving transparency
Negative
- None.
Insights
TL;DR: The transaction reflects a completed acquisition where equity holders received a fixed cash consideration plus contingent value rights, eliminating reported public holdings.
The Form 4 documents the mechanical securities conversion that follows a merger: all classes of the issuer's equity were cancelled and converted into $1.247 cash per share and a CVR. The large aggregate disposals reported—over 10 million shares indirectly and several million non-voting shares—are consistent with a contractually mandated conversion rather than market sales. For investors, this is a material liquidity event that ends the filer’s public equity exposure and replaces equity upside with a CVR and fixed cash consideration.
TL;DR: The filing discloses standard insider reporting after a change-in-control; beneficial ownership disclosures show holdings held through related entities.
The report identifies the reporting person as a director and 10% owner and shows pre-merger holdings held indirectly through Topsoe Holding A/S and Pillarcater LLC, with disclaimers of shared voting or pecuniary power. The Form 4 properly records the post-transaction beneficial ownership as zero. This filing documents compliance with Section 16 reporting obligations following a corporate transaction, and highlights the use of affiliated entities and trusts in holding arrangements.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Non-Voting Common Stock | 5,044,295 | $0.00 | -- |
| Disposition | Common Stock | 54,235 | $0.00 | -- |
| Disposition | Common Stock | 10,400,564 | $0.00 | -- |
| Disposition | Common Stock | 9,800 | $0.00 | -- |
Footnotes (1)
- Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock and Non-Voting Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement. Prior to the Merger, the shares were held directly by Topsoe Holding A/S. Jakob Haldor Topsoe, Christina Teng Topsoe, Anne Haugwitz-Hardenberg-Reventlow, Emil Oigaard, Thomas Schleicher and Birgitte Nielsen, members of the board of directors of Topsoe Holding A/S, may be deemed to share voting and investment power with respect to the shares reported herein and disclaim beneficial ownership of such shares, except to the extent of his or her pecuniary interest therein, if any. Prior to the Merger, the shares were held by Pillarcater LLC. The Reporting Person is the sole manager of Pillarcater LLC, which is wholly owned by CT Foundation (a South Dakota Trust) of which the Reporting Person is the sole beneficiary. Prior to the Merger, the shares of Non-Voting Common Stock were convertible into the Issuer's Common Stock on a 1-for-1 basis (subject to a 4.99% beneficial ownership limitation that may be increased or decreased by the holder of such shares) and had no expiration date.
